Abstract:3614 Background: The aim of this study is to compare clinical outcomes between two groups of different chemoradiation Regimens. Methods: Eligible patients were randomly assigned to Patients received either IMRT to the pelvis of 50 Gy/25Fxs concurrent with oxaliplatin 50 mg/m2 weekly and capecitabine 625 mg/m2 bid d1–5 weekly (Arm A), or IMRT to the pelvis of 50 Gy/25Fxs and a concomitant boost of 5 Gy to the primary tumor in 25 fractions, followed by a cycle of XELOX two weeks after the completion of chemoradiotherapy (Arm B). Surgery was scheduled eight weeks after the completion of CRT. All patients were recommended to receive adjuvant CT regardless of pathological stages. A total of six cycles of XELOX chemotherapy was recommended including neoadjuvant and adjuvant period. The primary end point was pCR. Results: From February 2010 to December 2011, a total of 120 patients were randomly assigned to Arm A (n = 60) or Arm B (n = 60). One hundred and ten patients (Arm A = 53, Arm B = 57) underwent surgery, the other 10 patients didn’t receive surgery because of unresectable disease. Eight and 14 cases were evaluated as pCR in two groups respectively ( p= .157). Tumor response was further classified into good response and poor response, the former was defined as ypT0N0, ypT1-2N0 and ypT0N1a. The rate of good responses were 30.0% and 55% ( p= .006). No significant differences were found in grade 3 or 4 acute adverse events during the treatment between the two groups. However, number of patients who had delayed incision healing was 13 and 3 patients ( p= .007). There were no statistical differences in OS ( p= .553), DFS ( p= .349) and local-regional control ( p= .856) between the two groups. In the univariate analysis, N stage, MRF involvement and tumor response had significant impacts on OS, DFS and LC. In the multivariate analysis, MRF involvement had significant impacts on OS ( p= .02), DFS ( p= .01) and LC ( p= .01). Conclusions: A dose-intensified radiotherapy in neoadjuvant chemoradiotherapy demonstrated contribution to tumor regression with acceptable toxicity, but led delayed incision healing after surgery. The impact of MRF involvement on survival merits further investigation. Clinical trial information: NCT01064999.

Effects Of Neoadjuvant Chemotherapy On Respiratory Function In Patients With Breast Cancer

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

Effects of Core Needle Biopsy and Subsequent Neoadjuvant Chemotherapy on Molecular Alterations and Outcome in Breast Cancer

A Single-Center, Randomized, Parallel Controlled Study Comparing the Efficacy and Safety Aspects of Three Anthracycline-Based Regimens As Neoadjuvant Chemotherapy in Primary Breast Cancer

Effect of Neoadjuvant Immunotherapy Combined with Chemotherapy on Pulmonary Function and Postoperative Pulmonary Complications in Esophageal Cancer: A Retrospective Study

[Effect of chemotherapy on the quality of life of lung cancer patients]

Evaluation of adverse effects induced by three different regimens used as neoadjuvant chemotherapy for local advanced breast cancer

Relationship Between Tumor Markers, ER/PR, HER2, Ki67 and CyclinA2 and Clinical Efficacy of Neoadjuvant Chemotherapy

[Impact of Neoadjuvant Immunotherapy on Pulmonary Function and Perioperative Outcomes in Patients with Resectable Non-Small Cell Lung Cancer].

Clinical Study of Different Regimens As Neoadjuvant Chemotherapy for Local Advanced Breast Cancer

Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: A phase II randomized trial

A Multicentric Prospective Study of the Effect of Neoadjuvant Chemotherapy with Cyclophosphamide,Fluorouracil and Pirarubicin on Localy Advanced Breast Cancer

[Clinical Evaluation of Effects from Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel in Cases of Locally Advanced Breast Cancer--comparative Study of Treatment with 2 and 4 Cycles].

[Effect of Neoadjuvant Chemotherapy on the Crispness of Pulmonary Vessels in Patients with Lung Cancer].

Assessment of the cardiorespiratory fitness and the quality of life of patients with breast cancer undergoing chemotherapy: a prospective study

Effect of Neoadjuvant Chemotherapy on the Serum Levels of Bone Turnover Markers in Women with Early-Stage Breast Cancer.

Analysis of Quality of Life and the Related Factors in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Neoadjuvant Chemotherapy: Friend or Foe

Assessment of neoadjuvant chemotherapy for breast cancer in 40 patients

Effects of Neoadjuvant Chemotherapy Combined with Radiotherapy in Patients with Advanced Esophageal Carcinoma

EFFECT OF NEOADJUVANT CHEMOTHERAPY USING PACLITAXEL COMBINED WITH CARBOPLATIN ON ADVANCED NON-SMALL CELL LUNG CANCER